ArticleWorld journal of transplantation2026
Outcomes of basiliximab
Article in World journal of transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Alemtuzumab or basiliximab: Rethinking induction choice beyond acute rejection in kidney transplantation.World journal of transplantation · 2026Review
- Letter to the Editor: Induction therapy as a long-term commitment: Lessons from comparative outcomes of alemtuzumab and basiliximab.World journal of transplantation · 2026Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of induction immunosuppression agents has improved kidney transplant outcomes, but selecting the optimal agent remains a point of debate.
aimTo compare the long-term outcomes of kidney transplant recipients receiving alemtuzumab
methodsKidney transplant recipients who received alemtuzumab or basiliximab induction from 2014 to 2019 across two nephrology centres in Northwest England were evaluated. Propensity score matching at a 1:1.5 ratio ensured comparability between cohorts. Baseline characteristics, immunosuppression regimens, and outcomes were analyzed. Linear, binary logistics and Cox proportional hazard regression models.
resultsA total of 436 recipients were included, with a median follow-up of 5.2 years. The matched cohort (
conclusionIn this propensity score-matched analysis, alemtuzumab induction was associated with lower graft function at 12 months and higher risks of viral infection, post-transplant malignancy, and graft loss compared with basiliximab. These findings highlight the need for further studies to confirm the long-term safety and effectiveness of alemtuzumab in kidney transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.